ACE and hydrops fetalis: Beta-blocker and ACE inhibitor/ARB prescription rates were highest in HFrEF (46.9% and 54.9%, respectively), reflecting landmark trials such as PARADIGM-HF [40] and DAPA-HF3 and existing data [41,42].